Intellus Advisors’s Pfizer PFE Stock Holding History

Intellus Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-31,247	Closed	-$792K	–	142
2025 Q1	$792K	Buy	+31,247	New	+$818K	0.14%	53

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Intellus Advisors's PFE Position: Q2 2025 in Review

Intellus Advisors sold out of Pfizer (PFE) in Q2 2025, closing a stake of 31,247 shares — an estimated $792K sold.

Intellus Advisors first reported a position in PFE in Q1 2025 and held it in 1 quarter. The position peaked at $792K in Q1 2025. 2,809 funds tracked by Wall St. Rank hold PFE as of Q2 2025.

Intellus Advisors reported no remaining Pfizer position as of Q2 2025 after selling out during the quarter.
Intellus Advisors sold 31,247 Pfizer shares in Q2 2025, an estimated $792K.
Intellus Advisors first reported a position in Pfizer in Q1 2025 and held it in 1 quarter.
Intellus Advisors's Pfizer position peaked at $792K in Q1 2025.
2,809 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.

Based on Intellus Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.